Exchange: NASDAQ·Updated 04:00 PM EDT

CANC News

News
all
press releases
AI, Cancer Vaccines, and Next-Gen Medicine
Could cancer vaccines and AI drive the next wave of healthcare innovation?
Zacks
More News
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks
Biotech ETF (CANC) Hits New 52-Week High
CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.
Zacks
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%
H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.
Stocktwits
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Zacks
Why Did GLUE Stock Surge Over 50% In Premarket Today?
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.
Stocktwits
Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
Tema ETFs (Tema), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (CANC) has surpassed $100m in assets under management (AUM) two...
Business Wire
Be Thankful to These ETFs This Year
Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.
Zacks
AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said.
Stocktwits
Inside the Recent Strength in Biotech ETFs
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Zacks

Advertisement|Remove ads.